Prudential PLC Purchases New Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Prudential PLC acquired a new position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 172,283 shares of the company’s stock, valued at approximately $2,707,000.

Several other large investors have also recently bought and sold shares of RDY. AIA Group Ltd raised its position in shares of Dr. Reddy’s Laboratories by 441.7% during the fourth quarter. AIA Group Ltd now owns 145,150 shares of the company’s stock worth $2,292,000 after acquiring an additional 118,357 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in Dr. Reddy’s Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after purchasing an additional 9,373,412 shares during the last quarter. Van ECK Associates Corp raised its holdings in Dr. Reddy’s Laboratories by 609.4% during the 4th quarter. Van ECK Associates Corp now owns 5,838 shares of the company’s stock worth $92,000 after purchasing an additional 5,015 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in Dr. Reddy’s Laboratories by 400.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock valued at $8,373,000 after purchasing an additional 427,573 shares during the period. Finally, World Investment Advisors LLC bought a new position in shares of Dr. Reddy’s Laboratories in the 3rd quarter valued at about $3,459,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Trading Down 6.6 %

NYSE RDY opened at $12.37 on Friday. Dr. Reddy’s Laboratories Limited has a 12 month low of $12.36 and a 12 month high of $16.89. The stock has a 50-day simple moving average of $13.33 and a 200 day simple moving average of $14.50. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $10.32 billion, a PE ratio of 19.69 and a beta of 0.51.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Research analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analysts Set New Price Targets

Separately, Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.